Shamanic healing, a practice rooted in transcultural worldviews involving interaction with the spirit world, shows potential benefits and a low risk of harm when used as a clinical intervention. A review of medical literature found sixteen relevant publications, including one clinical trial, two case series, and ten case reports. The authors conclude that shamanic healing is feasible to investigate further, though more research is needed to clarify its benefits.
Group psilocybin therapy is feasible for low-income adults with depression in Oregon's regulated psilocybin program. In an open-label study, 20 participants began treatment and 19 completed two psilocybin administration sessions one week apart, with preparation and integration sessions online. No severe adverse events occurred; participants rated satisfaction 4.8 out of 5, reporting moderate to high benefit and no harm. Exploratory outcomes showed a significant decrease in Hamilton Depression scores with a strong effect size (Cohen's d = 1.89), and all eight domains of the PROMIS-29 significantly improved with effect sizes from 0.667 to 1.774. Further research with comparator groups is warranted.